Financhill
Buy
51

PGNY Quote, Financials, Valuation and Earnings

Last price:
$22.77
Seasonality move :
-0.69%
Day range:
$22.28 - $23.09
52-week range:
$13.39 - $33.84
Dividend yield:
0%
P/E ratio:
40.00x
P/S ratio:
1.89x
P/B ratio:
4.61x
Volume:
636.3K
Avg. volume:
1.4M
1-year change:
-29.39%
Market cap:
$1.9B
Revenue:
$1.2B
EPS (TTM):
$0.57

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
PGNY
Progyny
$307.8M $0.45 11.16% 161.18% $26.75
ALHC
Alignment Healthcare
$888.3M -$0.07 41.56% -84% $17.78
CI
The Cigna Group
$60.4B $6.35 2.03% 31.99% $363.05
CLOV
Clover Health Investments
$466.9M -$0.07 34.59% -75% $4.75
NEUE
NeueHealth
$270.1M -$4.18 -10.61% -86.91% $7.00
OSCR
Oscar Health
$2.9B $0.81 32.34% 45.16% $19.36
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
PGNY
Progyny
$22.80 $26.75 $1.9B 40.00x $0.00 0% 1.89x
ALHC
Alignment Healthcare
$16.77 $17.78 $3.2B -- $0.00 0% 1.18x
CI
The Cigna Group
$335.18 $363.05 $91.7B 27.38x $1.51 1.7% 0.39x
CLOV
Clover Health Investments
$3.32 $4.75 $1.7B -- $0.00 0% 1.24x
NEUE
NeueHealth
$6.78 $7.00 $58.5M -- $0.00 0% 0.06x
OSCR
Oscar Health
$13.05 $19.36 $3.3B -- $0.00 0% 0.39x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
PGNY
Progyny
-- -0.288 -- 2.75x
ALHC
Alignment Healthcare
76.3% 1.920 14.89% 1.78x
CI
The Cigna Group
43.79% 0.336 42.17% 0.77x
CLOV
Clover Health Investments
-- 3.602 -- 1.47x
NEUE
NeueHealth
-88.93% -1.591 19.85% 0.32x
OSCR
Oscar Health
22.81% 2.511 8.89% 0.96x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
PGNY
Progyny
$63.4M $15.8M 11.14% 11.14% 5.29% $50.3M
ALHC
Alignment Healthcare
$86.3M -$22.5M -37.65% -101.38% -3.65% -$18M
CI
The Cigna Group
-- -- 4.6% 8.07% 3.61% $4.9B
CLOV
Clover Health Investments
$93.9M -$21.4M -13.55% -13.55% -6.38% -$86.1M
NEUE
NeueHealth
$47.7M -$28.6M -1375.06% -3241.93% -15.86% -$25.2M
OSCR
Oscar Health
-- -- 1.91% 2.46% -6.17% $340M

Progyny vs. Competitors

  • Which has Higher Returns PGNY or ALHC?

    Alignment Healthcare has a net margin of 3.53% compared to Progyny's net margin of -4.43%. Progyny's return on equity of 11.14% beat Alignment Healthcare's return on equity of -101.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    PGNY
    Progyny
    21.26% $0.12 $422.1M
    ALHC
    Alignment Healthcare
    12.31% -$0.16 $422.4M
  • What do Analysts Say About PGNY or ALHC?

    Progyny has a consensus price target of $26.75, signalling upside risk potential of 17.33%. On the other hand Alignment Healthcare has an analysts' consensus of $17.78 which suggests that it could grow by 6.01%. Given that Progyny has higher upside potential than Alignment Healthcare, analysts believe Progyny is more attractive than Alignment Healthcare.

    Company Buy Ratings Hold Ratings Sell Ratings
    PGNY
    Progyny
    4 6 0
    ALHC
    Alignment Healthcare
    6 3 0
  • Is PGNY or ALHC More Risky?

    Progyny has a beta of 1.372, which suggesting that the stock is 37.195% more volatile than S&P 500. In comparison Alignment Healthcare has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock PGNY or ALHC?

    Progyny has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alignment Healthcare offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Progyny pays -- of its earnings as a dividend. Alignment Healthcare pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PGNY or ALHC?

    Progyny quarterly revenues are $298.4M, which are smaller than Alignment Healthcare quarterly revenues of $701.2M. Progyny's net income of $10.5M is higher than Alignment Healthcare's net income of -$31.1M. Notably, Progyny's price-to-earnings ratio is 40.00x while Alignment Healthcare's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Progyny is 1.89x versus 1.18x for Alignment Healthcare. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PGNY
    Progyny
    1.89x 40.00x $298.4M $10.5M
    ALHC
    Alignment Healthcare
    1.18x -- $701.2M -$31.1M
  • Which has Higher Returns PGNY or CI?

    The Cigna Group has a net margin of 3.53% compared to Progyny's net margin of 2.17%. Progyny's return on equity of 11.14% beat The Cigna Group's return on equity of 8.07%.

    Company Gross Margin Earnings Per Share Invested Capital
    PGNY
    Progyny
    21.26% $0.12 $422.1M
    CI
    The Cigna Group
    -- $5.13 $73.2B
  • What do Analysts Say About PGNY or CI?

    Progyny has a consensus price target of $26.75, signalling upside risk potential of 17.33%. On the other hand The Cigna Group has an analysts' consensus of $363.05 which suggests that it could grow by 8.31%. Given that Progyny has higher upside potential than The Cigna Group, analysts believe Progyny is more attractive than The Cigna Group.

    Company Buy Ratings Hold Ratings Sell Ratings
    PGNY
    Progyny
    4 6 0
    CI
    The Cigna Group
    13 7 0
  • Is PGNY or CI More Risky?

    Progyny has a beta of 1.372, which suggesting that the stock is 37.195% more volatile than S&P 500. In comparison The Cigna Group has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.821%.

  • Which is a Better Dividend Stock PGNY or CI?

    Progyny has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Cigna Group offers a yield of 1.7% to investors and pays a quarterly dividend of $1.51 per share. Progyny pays -- of its earnings as a dividend. The Cigna Group pays out 45.63% of its earnings as a dividend. The Cigna Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios PGNY or CI?

    Progyny quarterly revenues are $298.4M, which are smaller than The Cigna Group quarterly revenues of $65.7B. Progyny's net income of $10.5M is lower than The Cigna Group's net income of $1.4B. Notably, Progyny's price-to-earnings ratio is 40.00x while The Cigna Group's PE ratio is 27.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Progyny is 1.89x versus 0.39x for The Cigna Group. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PGNY
    Progyny
    1.89x 40.00x $298.4M $10.5M
    CI
    The Cigna Group
    0.39x 27.38x $65.7B $1.4B
  • Which has Higher Returns PGNY or CLOV?

    Clover Health Investments has a net margin of 3.53% compared to Progyny's net margin of -6.56%. Progyny's return on equity of 11.14% beat Clover Health Investments's return on equity of -13.55%.

    Company Gross Margin Earnings Per Share Invested Capital
    PGNY
    Progyny
    21.26% $0.12 $422.1M
    CLOV
    Clover Health Investments
    27.87% -$0.04 $341.1M
  • What do Analysts Say About PGNY or CLOV?

    Progyny has a consensus price target of $26.75, signalling upside risk potential of 17.33%. On the other hand Clover Health Investments has an analysts' consensus of $4.75 which suggests that it could grow by 43.07%. Given that Clover Health Investments has higher upside potential than Progyny, analysts believe Clover Health Investments is more attractive than Progyny.

    Company Buy Ratings Hold Ratings Sell Ratings
    PGNY
    Progyny
    4 6 0
    CLOV
    Clover Health Investments
    2 2 0
  • Is PGNY or CLOV More Risky?

    Progyny has a beta of 1.372, which suggesting that the stock is 37.195% more volatile than S&P 500. In comparison Clover Health Investments has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock PGNY or CLOV?

    Progyny has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Clover Health Investments offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Progyny pays -- of its earnings as a dividend. Clover Health Investments pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PGNY or CLOV?

    Progyny quarterly revenues are $298.4M, which are smaller than Clover Health Investments quarterly revenues of $337M. Progyny's net income of $10.5M is higher than Clover Health Investments's net income of -$22.1M. Notably, Progyny's price-to-earnings ratio is 40.00x while Clover Health Investments's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Progyny is 1.89x versus 1.24x for Clover Health Investments. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PGNY
    Progyny
    1.89x 40.00x $298.4M $10.5M
    CLOV
    Clover Health Investments
    1.24x -- $337M -$22.1M
  • Which has Higher Returns PGNY or NEUE?

    NeueHealth has a net margin of 3.53% compared to Progyny's net margin of -1.17%. Progyny's return on equity of 11.14% beat NeueHealth's return on equity of -3241.93%.

    Company Gross Margin Earnings Per Share Invested Capital
    PGNY
    Progyny
    21.26% $0.12 $422.1M
    NEUE
    NeueHealth
    20.52% -$1.94 -$181.5M
  • What do Analysts Say About PGNY or NEUE?

    Progyny has a consensus price target of $26.75, signalling upside risk potential of 17.33%. On the other hand NeueHealth has an analysts' consensus of $7.00 which suggests that it could grow by 3.25%. Given that Progyny has higher upside potential than NeueHealth, analysts believe Progyny is more attractive than NeueHealth.

    Company Buy Ratings Hold Ratings Sell Ratings
    PGNY
    Progyny
    4 6 0
    NEUE
    NeueHealth
    0 1 0
  • Is PGNY or NEUE More Risky?

    Progyny has a beta of 1.372, which suggesting that the stock is 37.195% more volatile than S&P 500. In comparison NeueHealth has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock PGNY or NEUE?

    Progyny has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NeueHealth offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Progyny pays -- of its earnings as a dividend. NeueHealth pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PGNY or NEUE?

    Progyny quarterly revenues are $298.4M, which are larger than NeueHealth quarterly revenues of $232.6M. Progyny's net income of $10.5M is higher than NeueHealth's net income of -$2.7M. Notably, Progyny's price-to-earnings ratio is 40.00x while NeueHealth's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Progyny is 1.89x versus 0.06x for NeueHealth. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PGNY
    Progyny
    1.89x 40.00x $298.4M $10.5M
    NEUE
    NeueHealth
    0.06x -- $232.6M -$2.7M
  • Which has Higher Returns PGNY or OSCR?

    Oscar Health has a net margin of 3.53% compared to Progyny's net margin of -6.42%. Progyny's return on equity of 11.14% beat Oscar Health's return on equity of 2.46%.

    Company Gross Margin Earnings Per Share Invested Capital
    PGNY
    Progyny
    21.26% $0.12 $422.1M
    OSCR
    Oscar Health
    -- -$0.62 $1.3B
  • What do Analysts Say About PGNY or OSCR?

    Progyny has a consensus price target of $26.75, signalling upside risk potential of 17.33%. On the other hand Oscar Health has an analysts' consensus of $19.36 which suggests that it could grow by 48.33%. Given that Oscar Health has higher upside potential than Progyny, analysts believe Oscar Health is more attractive than Progyny.

    Company Buy Ratings Hold Ratings Sell Ratings
    PGNY
    Progyny
    4 6 0
    OSCR
    Oscar Health
    1 2 1
  • Is PGNY or OSCR More Risky?

    Progyny has a beta of 1.372, which suggesting that the stock is 37.195% more volatile than S&P 500. In comparison Oscar Health has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock PGNY or OSCR?

    Progyny has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oscar Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Progyny pays -- of its earnings as a dividend. Oscar Health pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PGNY or OSCR?

    Progyny quarterly revenues are $298.4M, which are smaller than Oscar Health quarterly revenues of $2.4B. Progyny's net income of $10.5M is higher than Oscar Health's net income of -$153.5M. Notably, Progyny's price-to-earnings ratio is 40.00x while Oscar Health's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Progyny is 1.89x versus 0.39x for Oscar Health. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PGNY
    Progyny
    1.89x 40.00x $298.4M $10.5M
    OSCR
    Oscar Health
    0.39x -- $2.4B -$153.5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Palantir Stock a Millionaire Maker?
Is Palantir Stock a Millionaire Maker?

Palantir (NASDAQ:PLTR) has shot upward over the last year and…

Is QuantumScape a Buy Now?
Is QuantumScape a Buy Now?

QuantumScape (NYSE:QS) is an innovative EV battery company that specializes…

Is Vertex Stock Still a Good Buy?
Is Vertex Stock Still a Good Buy?

Over the past ten years or so, Vertex Pharmaceuticals (NASDAQ:…

Stock Ideas

Sell
50
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
68
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 36x

Buy
59
Is NVDA Stock a Buy?

Market Cap: $2.7T
P/E Ratio: 38x

Alerts

Buy
62
RGC alert for May 2

Regencell Bioscience Holdings [RGC] is up 20.58% over the past day.

Sell
36
WGS alert for May 2

GeneDx Holdings [WGS] is down 6.85% over the past day.

Sell
42
VICR alert for May 2

Vicor [VICR] is down 1.28% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock